Effective management of lower urinary tract dysfunction in idiopathic Parkinson's disease

International Journal of Urology

Volumn 20, Issue 1, 2013, Pages 79-84

  Kapoor, Sona ^a   Bourdoumis, Andreas ^a   Mambu, Lewis ^a   Barua, Jayanta ^a  

^a KING GEORGE HOSPITAL   (United Kingdom)

Author keywords

Bladder dysfunction; Management; Multiple system atrophy; Parkinsonism; Urinary symptoms

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BACLOFEN; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; DANTROLENE; DESMOPRESSIN; DIAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; IMIPRAMINE; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ANTERIOR CINGULATE; BASAL GANGLION; BLADDER CAPACITY; BLADDER DYSFUNCTION; CONSERVATIVE TREATMENT; DETRUSOR MUSCLE; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; ELECTROACUPUNCTURE; FRONTAL CORTEX; HUMAN; IMPAIRED BLADDER EMPTYING; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MINIMALLY INVASIVE PROCEDURE; MOTOR DYSFUNCTION; NEUROGENIC BLADDER; NEUROMODULATION; NOCTURIA; OVERACTIVE BLADDER; PARKINSON DISEASE; PATHOPHYSIOLOGY; POLYURIA; PREVALENCE; PRIORITY JOURNAL; RESIDUAL URINE; REVIEW; SHY DRAGER SYNDROME; STRIATONIGRAL DEGENERATION; THALAMUS; TRANSCRANIAL MAGNETIC STIMULATION; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URODYNAMICS;

HUMANS; LOWER URINARY TRACT SYMPTOMS; PARKINSON DISEASE; PREVALENCE;

EID: 84871871372     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03220.x     Document Type: Review

References (46)

1. Murnaghan GF. Neurogenic disorders of the bladder in Parkinsonism. Br. J. Urol. 1961; 33: 403-409.
2. Campos-Sousa RN, Quagliato E, da Silva BB etal. Urinary symptoms in Parkinson's disease: prevalence and associated factors. Arq. Neuropsiquiatr. 2003; 61 (2B): 359-363.
3. Salinas JM, Berger Y, De La Rocha RE etal. Urological evaluation in the Shy Drager syndrome. J. Urol. 1986; 135: 741-743.
4. Gray R, Stern G, Malone-Lee J. Lower urinary tract dysfunction in Parkinson's disease: changes relate to age and not disease. Age Ageing 1995; 24: 499-504.
5. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J. Neurol. Neurosurg. Psychiatry 2000; 68: 429-433.
6. Lemack GE, Dewey RB, Roehrborn CG etal. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology 2000; 56: 250-254.
7. Sakakibara R, Uchiyama T, Yamanishi T etal. Bladder and bowel dysfunction in Parkinson's disease. J. Neural Transm. 2008; 115: 443-460.
8. Ransmayr GN, Holliger S, Schletterer K etal. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology 2008; 70: 299-303.
9. Ragab MM, Mohammed ES. Idiopathic Parkinson's disease patients at the Urologic Clinic. Neurourol. Urodyn. 2011; 20: 1258-1261.
10. Sammour ZM, Gomes CM, Barbosa ER etal. Voiding dysfunction in patients with Parkinson's disease: impact of neurological impairment and clinical parameters. Neurourol. Urodyn. 2009; 28: 510-515.
11. Fowler CJ, Dalton C, Panicker JN. Review of neurologic diseases for the urologist. Urol. Clin. North Am. 2010; 37: 517-526.
12. Merola A, Zibetti M, Angrisano S etal. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients. Brain 2011; 134 (Pt 7): 2074-2084.
13. Araki I, Kitahara M, Oida T etal. Voiding dysfunction and Parkinson's disease: Urodynamic abnormalities and urinary symptoms. J. Urol. 2000; 164: 1640-1643.
14. de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br. J. Pharmacol. 2006; 147 (Suppl 2): S25-40.
15. Seki S, Igawa Y, Kaidoh K etal. Role of Dopamine D1 and D1 receptors in the micturition reflex in conscious rats. Neurourol. Urodyn. 2001; 20: 105-113.
16. Braak H, Ghebremedhin E, Rub U etal. Stages in the development of Parkinson's disease related pathology. Cell Tissue Res. 2004; 318: 121-134.
17. Winge K, Werdelin L, Nielsen K, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol. Urodyn. 2004; 23: 689-696.
18. Pannek J, Stohrer M, Blok B etal. Guidelines on Neurogenic Lower Urinary Tract Dysfunction. EAU Guidelines 2012, pp. 8-36.
19. Hineno T, Mizobuchi M, Hiratani K etal. Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in dogs. Brain Res. 1992; 580: 92-99.
20. Sakakibara R, Shinotoh H, Uchiyama T etal. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton. Neurosci. 2001; 92: 76-85.
21. Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson's disease. Neurobiol. Dis. 2012; 46: 565-571.
22. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, Prevalence, Symptoms and Management. Mov. Dis. 2006; 21: 737-745.
23. Winge K, Skau AM, Stimpel H, Nielsen KK, Werdelin L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol. Urodyn. 2006; 25: 116-122.
24. Defreitas GA, Lemack GE, Zimmern PE, Dewey RB etal. Distinguishing neurogenic from non-neurogenic dtrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without Parkinson's disease. Urology 2003; 62: 651-655.
25. Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J. Urol. 1994; 151: 1336-1341.
26. Sakakibara R, Hattori T, Uchiyama T, Kita K etal. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? J. Neurol. Neurosurg. Psychiatry 2000; 68: 65-69.
27. Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br. J. Urol. 1997; 80: 100-104.
28. Burn DJ, Jaros E. Multiple system atrophy: cellular and Molecular pathology. Mol. Pathol. 2001; 54: 419-426.
29. Wenning GK, Gesser F, Stampfer-Kountchev M, Tison F. Multiple system atrophy: an update. Mov Dis. 2003; 18 (Suppl 6): S34-42.
30. Papatsoris AG, Deliveliotis C, Singer C, Papapetropoulos S. Erectile dysfunction in Parkinson's disease. Urology 2006; 67: 447-451.
31. Giannantoni A, Rossi A, Mearini E etal. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J. Urol. 2009; 182: 1453-1457.
32. Kabay SC, Kabay S, Yucel M etal. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease. Neurourol. Urodyn. 2009; 28: 62-67.
33. Andersson KE. Treatment of overactive bladder: other drug mechanisms. Urology 2000; 55: 51-57.
34. Appel RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997; 50: 90-96.
35. Sussman D, Garely A. Treatment of overactive bladder with once daily extended release tolterodine or oxybutinin: the antimuscarinic clinical effectiveness trial (ACET). Curr. Med. Res. Opin. 2002; 18: 177-184.
36. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospiumchloride and oxybutinin on the central nervous system. J. Clin. Pharmacol. 2001; 41: 636-644.
37. Sotolongo JR. Voiding dysfunction in Parkinson's disease. Semin. Neurol. 1988; 892: 166-169.
38. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum toxin A on detrusor sphincter dyssynergia in spinal cord injury patients. J. Urol. 1988; 139: 919-922.
39. Giannantoni A, Conte A, Proietti S etal. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J. Urol. 2011; 186: 960-964.
40. Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am. J. Obstet. Gynecol. 2007; 197: 96e1-965.
41. Krivoborodov GG, Gekht AB, Korshunova ES. Tibial neuromodulation in the treatment of neurogenic detrusor hyperactivity in patients with Parkinson's disease. Urologiia 2006; 4: 3-6.
42. Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and Parkinson's disease: should transurethral resection of the prostate be avoided? J. Urol. 2009; 181: 2209-2213.
43. Routh JC, Crimmins CR, Leibovich BC, Elliott DS. Impact of Parkinson's disease on continence after radical prostatectomy. Urology 2006; 68: 575-577.
44. Chen YL, Feng WJ, Zhang XL. Parkinson's disease combined with overactive bladder syndrome treated with acupuncture and medication. Zhongguo Zhen Jiu 2012; 32: 215-218.
45. Brusa L, Finazzi Agrò E, Petta F etal. Effects of inhibitory rTMS on bladder function in Parkinson's disease patients. Mov. Disord. 2009; 24: 445-448.
46. Zibetti M, Merola A, Rizzi L etal. Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease. Mov. Disord. 2011; 26: 2327-2334.